Skip to Main Content

Biogen said Wednesday that the submission of a U.S. marketing application for its Alzheimer’s drug aducanumab has been delayed until the summer.

The Cambridge, Mass.-based biotech had said previously the drug would be filed with the Food and Drug Administration in “early 2020.” The submission will now occur in the third quarter, following a scheduled meeting with FDA staff, Biogen said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!